COMMUNIQUÉS West-GlobeNewswire

New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
15/04/2024
APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN 1 IgAN is a heterogeneous, progressive, rare kidney disease and [...]
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
15/04/2024
Bagsværd, Denmark, 15 April 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance [...]
Ezra, AI Leader in the Full Body MRI Space, Announces Partnership with Imaging Leader RAYUS Radiology
15/04/2024
The partnership will offer nationwide access to Ezra’s full-body MRI at 150 RAYUS locations across the country NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Ezra , the healthcare AI startup transforming early cancer [...]
Publication Annual Report – Annual Shareholders' Meeting
15/04/2024
Publication Annual Report – Annual Shareholders' Meeting Leuven, BELGIUM – April 15, 2024 – 05:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, has today published its [...]
Nika Pharmaceuticals, Inc. (NKPH) Purchased the Technologies for Three Drugs in Tablet Form and One Dietary Supplement
15/04/2024
HENDERSON, Nev., April 15, 2024 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH ) announces the purchase of four technologies for production of three generic drugs in tablet form and one dietary supplement [...]
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
15/04/2024
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory AL amyloidosis will be presented in Baltimore May 7-11, 2024 LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: [...]
Redemption Date Announced for Warrants
15/04/2024
Monday, May 6, 2024 is Last and Final Day to Exercise Warrants. Once Redeemed, the Warrants Will Cease to Exist and Have No Value. AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA [...]
Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary Products
15/04/2024
An important step in Kane becoming a market leader in the growing high-value wound care and dermatological markets WINNIPEG, Manitoba, April 15, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“ [...]
LifeLabs Celebrates National Medical Laboratory Week Recognizing Compassionate, Passionate, and Innovative Professionals
15/04/2024
Toronto, April 15, 2024 (GLOBE NEWSWIRE) -- This week, LifeLabs joins in celebrating the annual National Medical Laboratory Week, a significant event organized by the Canadian Society for Medical Laboratory Science. [...]
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
15/04/2024
Clinical trial expected to commence in mid-2024 to evaluate the safety and preliminary anti-tumor activity of TTX-MC138 BOSTON, April 15, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA [...]
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
15/04/2024
OCALA, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced that Charles Lapp, MD, is joining the company to help lead its efforts to develop Ampligen (rintatolimod) [...]
Novo Nordisk A/S - share repurchase programme
15/04/2024
Bagsværd, Denmark, 15 April 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Sienna Announces April Dividend
15/04/2024
MARKHAM, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
15/04/2024
MIAMI, April 15, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it has been accepted for a Featured Research Oral [...]
CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)
15/04/2024
BERKELEY HEIGHTS, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and [...]
Microbot Medical Shares Status Following Recent Geopolitical Events
15/04/2024
All Regulatory, Clinical, Operational and Pre-Commercial Activities Continue to Stay on Track Despite the On-going Situation in Israel Company Believes that Both Regulatory and Commercial Milestones to be Achieved in [...]
Mobile-health Network Solutions Makes History as First APAC Telehealth Company Listed on US Stock Exchange
15/04/2024
SINGAPORE, April 15, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR ), a pioneering Asia-Pacific (APAC) telehealth provider, celebrates its successful initial public offering (IPO) on the Nasdaq [...]
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
15/04/2024
- FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA) for brilaroxazine in [...]
The United States FDA Awards Orphan Drug Designation (ODD) to NM5072 for Treating Paroxysmal Nocturnal Hemoglobinuria (PNH)
15/04/2024
A Promising Treatment for PNH Patients The United States Food and Drug Administration (FDA) has awarded orphan drug designation (ODD) to NM5072 for the treatment of anemia in PNH patients. The ODD provides NM5072 with a [...]

Pages